Efficacy of single-stage breast-conserving treatment using multicatheter partial breast brachytherapy evaluated by GEC-ESTRO phase 3 trial.
Conclusions: Single-stage BCT using MCB-PBI offered similar tumor control rates compering to WBI. However, further research is needed to define the benefit for patients with an exclusion criteria. PMID: 29204163 [PubMed]
Adjuvant radiation after breast-conserving surgery remains the standard-of-care treatment for patients with ductal carcinoma in situ and early-stage invasive breast cancer. Multiple alternatives to standard whole-breast irradiation exist including accelerated partial-breast irradiation (APBI). Therefore, the purpose of this APBI guideline is to provide updated data for clinicians as well as recommendations regarding appropriate patient selection and techniques to deliver APBI.
ConclusionsRecurrence rates observed in this trial were comparable to those of the TARGIT-A and ELIOT trials as well as the retrospective TARGIT-R trial. The low complication rates previously reported by our group as well as the low recurrence rates reported in this study support the cautious use and continued study of IORT in selected women with low-risk breast cancer.
Abstract Accelerated partial breast irradiation (APBI) is an increasingly utilized modality for early stage breast cancer as part of breast conservation therapy (BCT). There remains concern regarding local recurrence, requiring more frequent post‐radiation surveillance imaging. The purpose of this study is to determine clinical significance of frequent surveillance in this perceived higher risk population. Patients treated at a community academic medical center from 2005 to 2013 with partial breast radiation were retrospectively identified. All patients were treated with lumpectomy followed by balloon based APBI. Diagnos...
ConclusionsThis case series of 78 patients having greater than 24 months of follow-up from a single institution provides important data regarding failure analysis with MammoSite™ accelerated partial breast irradiation. Our results show a higher rate of metastatic recurrence in the group of patients with positive nodal disease.
CONCLUSIONS: Accelerated partial breast irradiation using multicatheter brachytherapy with 32 Gy/8 fractions and 35 Gy/7 fractions for early breast cancer seems to be similar in terms of late side effects. According to our findings, APBI was also feasible for intermediate-risk of early breast cancer patients. PMID: 28533797 [PubMed - in process]
ConclusionAPBI in Japanese women provides satisfactory clinical results except for cosmetic outcomes. There is some difficulty with the assessment of fibrosis and cosmetic outcomes, especially in patients with small breasts.Clinical Trial Registration NumberUMIN000001677.
To report results for 415 patients treated at a single institution with APBI using interstitial multicatheter high dose rate brachytherapy (HDR BT) after breast conserving surgery for low risk invasive and in situ breast cancer.
We report our experience and outcomes with accelerated partial breast brachytherapy (APBI) for early stage breast cancer, both invasive and non-invasive breast cancers. The cancer was treated with breast-conserving therapy consisting of a lumpectomy followed by accelerated partial breast irradiation.
Lumpectomy cavity radiotherapy boost after breast conserving surgery and whole breast irradiation reduces local cancer recurrence. This boost is typically delivered with external beam photons or electrons, encompassing the postoperative surgical cavity and a surrounding margin of normal breast tissue. External beam radiotherapy boost correlates with increased rates of breast fibrosis and may impair cosmetic outcomes. Multicatheter breast brachytherapy (MCBB) is an approach to deliver dose-escalated high dose rate radiation to the lumpectomy cavity while limiting additional radiation exposure to normal breast tissue and adjacent organs.
We report the clinical outcomes for such patients treated at Exeter Hospital with electronic 50Kv brachytherapy alone as Adjuvant Radiation Treatment for Early-Stage Breast Cancer.